Status:
RECRUITING
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
Lead Sponsor:
Guangzhou Burning Rock Dx Co., Ltd.
Collaborating Sponsors:
West China Hospital
Conditions:
Cancer
Early Detection of Cancer
Eligibility:
All Genders
40-75 years
Phase:
NA
Brief Summary
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
Detailed Description
Participants will receive the OverC multi-cancer detection blood test along with standard-of-care screening, whose results will be returned to health care providers and participants. The diagnostic pr...
Eligibility Criteria
Inclusion
- Participants must be able to provide a written informed consent form
- Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form
- Participants must be able to provide blood samples for study tests
- Participants must be between 40 and 75 years old
Exclusion
- Individuals who have an acute infection or inflammation within 14 days prior to recruitment
- Individuals with cancer-associated clinical symptoms or suspected of cancer
- Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
- Recipient of blood transfusion within 7 days prior to recruitment
- Individuals who have pure ground-glass opacity
- Unable to provide blood samples for the multi-cancer early detection blood test
- Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests
- Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment
- Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment
- Individuals with hemorrhagic diseases
- Individuals with autoimmune diseases
- Individuals who are pregnant or lactating
- Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
12500 Patients enrolled
Trial Details
Trial ID
NCT05227534
Start Date
June 1 2022
End Date
December 31 2028
Last Update
July 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610044